hero section gradient
15 handpicked stocks

Biotech's IP Moat

This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.

Author avatar

Han Tan | Market Analyst

Published on July 11

Your Basket's Financial Footprint

Market capitalisation breakdown for 'Biotech's IP Moat' basket.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and closer tracking to broad market moves, reducing idiosyncratic risk.
  • Suitable as a core holding for diversified portfolios rather than a speculative, high-growth allocation.
  • Expect steadier long-term value; avoid anticipating explosive short-term gains.
Total Market Cap
  • MRNA: $10.74B

  • BNTX: $25.18B

  • CRSP: $6.58B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Patents are the crown jewels of biotech companies. Recent high-profile disputes between Pfizer, BioNTech, and Moderna highlight how valuable intellectual property is in this sector. Companies with strong patents can protect their innovations, command premium pricing, and generate licensing revenue for years.

2

What You Need to Know

This collection focuses on companies with "IP moats" - strong patent portfolios that protect their innovations from competitors. These stocks typically represent higher-risk, higher-reward investments in cutting-edge fields like gene editing, cell therapy, and RNA-based medicine, where breakthroughs can lead to substantial returns.

3

Why These Stocks

These companies were selected because they either have established intellectual property in revolutionary technologies or are developing the next generation of patentable breakthroughs. Their business models often depend on securing and defending foundational patents that can provide sustainable advantages in highly competitive markets.

Why You'll Want to Watch These Stocks

⚖️

The Patent Power Play

The Pfizer-Moderna lawsuit has put a spotlight on how valuable intellectual property can be in biotech. Companies that win these battles can secure billions in licensing fees or damages, creating massive shareholder value overnight.

🧬

Tomorrow's Breakthroughs Today

These companies aren't just developing treatments, they're creating entirely new ways to fight disease. Their groundbreaking platforms in gene editing and cell therapy could revolutionize medicine and generate huge returns for early investors.

🛡️

Built-in Competitive Protection

Strong patents act like a moat around a castle, keeping competitors at bay for years or even decades. This protection allows these companies to maintain premium pricing and higher profit margins than other sectors.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Streaming Power Dynamics Explained | Content Wars

Streaming Power Dynamics Explained | Content Wars

The resolution of the content dispute between Disney and Google's YouTube TV highlights the critical interdependence of content creators and distributors. This dynamic creates an investment opportunity in companies that are central to the streaming ecosystem, from content production to platform delivery.

Jeep Hybrid Recall Overview: Market Shift Analysis

Jeep Hybrid Recall Overview: Market Shift Analysis

Stellantis is recalling nearly 113,000 Jeep plug-in hybrids because of a serious engine defect, creating potential investment opportunities. This theme focuses on competing automakers and aftermarket parts suppliers that may benefit from a shift in consumer confidence and repair needs.

Frequently Asked Questions